BACKGROUND: The incubation of cue-induced drug craving in rodents provides a model of persistent vulnerability to craving and relapse in human addicts. After prolonged withdrawal, incubated cocaine craving depends on strengthening of nucleus accumbens (NAc) core synapses through incorporation of Ca2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (CP-AMPARs). Through metabotropic glutamate receptor 1 (mGluR1)-mediated synaptic depression, mGluR1 positive allosteric modulators remove CP-AMPARs from these synapses and thereby reduce cocaine craving. This study aimed to determine if similar plasticity accompanies incubation of methamphetamine craving. METHODS: Rats self-administered saline or methamphetamine under extended-access conditions. Cue-induced seeking tests demonstrated incubation of methamphetamine craving. After withdrawal periods ranging from 1 to >40 days, rats underwent one of the following procedures: 1) whole-cell patch clamp recordings to characterize AMPAR transmission, 2) intra-NAc core injection of the CP-AMPAR antagonist 1-naphthyl acetyl spermine followed by a seeking test, or 3) systemic administration of a mGluR1 positive allosteric modulator followed by a seeking test. RESULTS: Incubation of methamphetamine craving was associated with CP-AMPAR accumulation in NAc core, and both effects were maximal after ~1 week of withdrawal. Expression of incubated craving was decreased by intra-NAc core 1-naphthyl acetyl spermine injection or systemic mGluR1 positive allosteric modulator administration. CONCLUSIONS: These results are the first to demonstrate a role for the NAc in the incubation of methamphetamine craving and describe adaptations in synaptic transmission associated with this model. They establish that incubation of craving and associated CP-AMPAR plasticity occur much more rapidly during withdrawal from methamphetamine compared with cocaine. However, a common mGluR1-based therapeutic strategy may be helpful for recovering cocaine and methamphetamine addicts.
BACKGROUND: The incubation of cue-induced drug craving in rodents provides a model of persistent vulnerability to craving and relapse in human addicts. After prolonged withdrawal, incubated cocaine craving depends on strengthening of nucleus accumbens (NAc) core synapses through incorporation of Ca2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (CP-AMPARs). Through metabotropic glutamate receptor 1 (mGluR1)-mediated synaptic depression, mGluR1 positive allosteric modulators remove CP-AMPARs from these synapses and thereby reduce cocaine craving. This study aimed to determine if similar plasticity accompanies incubation of methamphetamine craving. METHODS:Rats self-administered saline or methamphetamine under extended-access conditions. Cue-induced seeking tests demonstrated incubation of methamphetamine craving. After withdrawal periods ranging from 1 to >40 days, rats underwent one of the following procedures: 1) whole-cell patch clamp recordings to characterize AMPAR transmission, 2) intra-NAc core injection of the CP-AMPAR antagonist 1-naphthyl acetyl spermine followed by a seeking test, or 3) systemic administration of a mGluR1 positive allosteric modulator followed by a seeking test. RESULTS: Incubation of methamphetamine craving was associated with CP-AMPAR accumulation in NAc core, and both effects were maximal after ~1 week of withdrawal. Expression of incubated craving was decreased by intra-NAc core 1-naphthyl acetyl spermine injection or systemic mGluR1 positive allosteric modulator administration. CONCLUSIONS: These results are the first to demonstrate a role for the NAc in the incubation of methamphetamine craving and describe adaptations in synaptic transmission associated with this model. They establish that incubation of craving and associated CP-AMPAR plasticity occur much more rapidly during withdrawal from methamphetamine compared with cocaine. However, a common mGluR1-based therapeutic strategy may be helpful for recovering cocaine and methamphetamine addicts.
Authors: Carrie R Ferrario; Jessica A Loweth; Mike Milovanovic; Kerstin A Ford; Gregorio L Galiñanes; Li-Jun Heng; Kuei Y Tseng; Marina E Wolf Journal: Neuropharmacology Date: 2011-01-27 Impact factor: 5.250
Authors: Jamie Peters; Michael D Scofield; Shannon M Ghee; Jasper A Heinsbroek; Carmela M Reichel Journal: Neuropsychopharmacology Date: 2015-09-14 Impact factor: 7.853
Authors: Jessica A Loweth; Andrew F Scheyer; Mike Milovanovic; Amber L LaCrosse; Eden Flores-Barrera; Craig T Werner; Xuan Li; Kerstin A Ford; Tuan Le; M Foster Olive; Karen K Szumlinski; Kuei Y Tseng; Marina E Wolf Journal: Nat Neurosci Date: 2013-11-24 Impact factor: 24.884
Authors: Conor H Murray; Jessica A Loweth; Mike Milovanovic; Michael T Stefanik; Aaron J Caccamise; Hubert Dolubizno; Jonathan R Funke; M Foster Olive; Marina E Wolf Journal: Neuropsychopharmacology Date: 2019-05-30 Impact factor: 7.853
Authors: B M Siemsen; C M Reichel; K C Leong; C Garcia-Keller; C D Gipson; S Spencer; J A McFaddin; K N Hooker; P W Kalivas; M D Scofield Journal: Neuroscience Date: 2019-03-26 Impact factor: 3.590
Authors: Atul P Daiwile; Subramaniam Jayanthi; Bruce Ladenheim; Michael T McCoy; Christie Brannock; Jennifer Schroeder; Jean Lud Cadet Journal: Int J Neuropsychopharmacol Date: 2019-11-01 Impact factor: 5.176
Authors: Karen K Szumlinski; Kevin D Lominac; Rianne R Campbell; Matan Cohen; Elissa K Fultz; Chelsea N Brown; Bailey W Miller; Sema G Quadir; Douglas Martin; Andrew B Thompson; Georg von Jonquieres; Matthias Klugmann; Tamara J Phillips; Tod E Kippin Journal: Biol Psychiatry Date: 2016-10-13 Impact factor: 13.382
Authors: Xuan Li; Maria B Carreria; Kailyn R Witonsky; Tamara Zeric; Olivia M Lofaro; Jennifer M Bossert; Jianjun Zhang; Felicia Surjono; Christopher T Richie; Brandon K Harvey; Hyeon Son; Christopher W Cowan; Eric J Nestler; Yavin Shaham Journal: Biol Psychiatry Date: 2017-12-29 Impact factor: 13.382
Authors: Hannah M Cates; Xuan Li; Immanuel Purushothaman; Pamela J Kennedy; Li Shen; Yavin Shaham; Eric J Nestler Journal: Neuropsychopharmacology Date: 2018-07-20 Impact factor: 7.853